
    
      IAB2M is an approximately 80 kDA molecular weight antibody fragment (a "Minibody"). Limited
      (Phase 0/Proof-of-concept) patient experience with this biologic targeting agent has been
      previously obtained with SPECT imaging Ex-US, demonstrating targeting of soft tissue and bone
      lesions in advanced metastatic prostate cancer.
    
  